Concert Pharmaceuticals Inc. (NASDAQ:CNCE) traded up 2.6% during trading on Friday . The company traded as high as $11.84 and last traded at $11.49, with a volume of 57,004 shares. The stock had previously closed at $11.20.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday. Brean Capital reiterated a “buy” rating on shares of Concert Pharmaceuticals in a report on Monday. Finally, Stifel Nicolaus assumed coverage on shares of Concert Pharmaceuticals in a report on Friday, July 1st. They set a “buy” rating and a $23.00 price target for the company. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. Concert Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $26.43.

The firm has a market cap of $257.71 million and a PE ratio of 13.93. The firm’s 50-day moving average price is $11.99 and its 200 day moving average price is $13.59.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by $0.18. Equities analysts predict that Concert Pharmaceuticals Inc. will post ($2.16) EPS for the current year.

In related news, CEO Roger D. Tung bought 19,610 shares of Concert Pharmaceuticals stock in a transaction on Wednesday, May 11th. The shares were purchased at an average price of $10.55 per share, for a total transaction of $206,885.50. Following the completion of the acquisition, the chief executive officer now owns 538,965 shares in the company, valued at $5,686,080.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

An institutional investor recently raised its position in Concert Pharmaceuticals stock. California Public Employees Retirement System increased its position in Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 22.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 103,700 shares of the company’s stock after buying an additional 18,700 shares during the period. California Public Employees Retirement System owned 0.47% of Concert Pharmaceuticals worth $1,967,000 as of its most recent SEC filing.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.